Chronos Archive seal
The Human Record

Emily Dickinson

Case HR-NI023-TD · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
December 10, 1830 – May 15, 1886
Synthetic DOB
1830-12-10
Index visit
1885-01-12 at age 54
Synthetic MRN
HR-NI023-SYN-TD

Teaching objective: Diagnose and manage stage G3a A2 chronic kidney disease with hypertension in a 54-year-old woman by KDIGO 1883 and the CMID kidney and blood pressure schedules: eGFR and albuminuria staging, KFRE, a maximum-dose ARB and an SGLT2 inhibitor with potassium and creatinine checks after each start, a statin, bone-mineral and anemia checks by stage, vaccines, NSAID avoidance, and sick-day guidance, while screening mood and anxiety without labeling a lifelong wish for solitude as a disorder, and delivering care at home or by video where that is safe.

Historical timeline

DateEventClaims
December 10, 1830Born in the family Homestead in Amherst, Massachusetts.CLM-0001
Late winter of 1848Removed from Mount Holyoke Female Seminary for about a month with lung congestion and a cough.CLM-0002
1851Consumptive symptoms; takes a glycerine prescription for two years.CLM-0003
Fall of 1863Eye affliction begins.CLM-0004
February 1864Consults a Boston ophthalmologist; treated while living in Cambridgeport from April to December.CLM-0004, CLM-0005
April to October 1865Repeats the eye treatment and is apparently cured.CLM-0004
October 1883Nervous prostration after a death in her family; ill health continues to her death.CLM-0010
May 15, 1886Dies in Amherst at 55; Bright's disease is entered on the death certificate.CLM-0013

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Emily Dickinson was born on December 10, 1830, in the family Homestead on Main Street in Amherst, Massachusetts. confirmed Emily Dickinson: Her Childhood and Youth (1830-1855) supports
D In the late winter of 1848 she was removed from Mount Holyoke Female Seminary for about a month because of lung congestion and a cough. confirmed Emily Dickinson's Health supports
D In 1851 she had symptoms then thought to be consumptive, consulted local and Boston doctors, and for two years took a glycerine prescription from a Boston tuberculosis specialist until the symptoms apparently subsided.
No diagnosis of tuberculosis is documented.
confirmed Emily Dickinson's Health supports
D By her own account an eye affliction began in the fall of 1863; in February 1864 she consulted the Boston ophthalmologist Henry Willard Williams, lived in Cambridgeport from April to December 1864 to be near him for treatment, and repeated the treatment from April to October 1865, after which she was apparently cured. confirmed Emily Dickinson's Health supports
Blanchard DL. Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD. Arch Ophthalmol. 2012;130(12):1591-1595. doi:10.1001/archophthalmol.2012.2365 supports
D The treatment required confinement in dim light, no reading, and writing only in pencil; she called her first stay in Cambridge eight months of Siberia. confirmed Emily Dickinson's Health supports
R No record of the eye diagnosis survives. Her main symptoms were sensitivity to light, aching eyes, and a restricted ability to do close work; iritis is considered the most likely explanation, and exotropia, a psychiatric cause, and hysterical hyperaesthesia of the retina have also been proposed.
Retrospective interpretations; the 2012 review offers a further possibility rather than a conclusion.
disputed Blanchard DL. Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD. Arch Ophthalmol. 2012;130(12):1591-1595. doi:10.1001/archophthalmol.2012.2365 supports
Emily Dickinson's Health supports
D Her withdrawal from normal social situations began in her mid-twenties; in later years she rarely went beyond the family Homestead and spoke with some visitors from behind a darkened door rather than face to face. confirmed Emily Dickinson's Health supports
Emily Dickinson: The Later Years (1865-1886) supports
R Scholars disagree whether her withdrawal was a deliberate artistic choice or had a medical origin, such as an anxiety condition.
No diagnosis is documented; labels such as agoraphobia or social anxiety are retrospective and disputed.
disputed Emily Dickinson's Health supports
R A 2013 review by Hirschhorn and Longsworth rejects a proposed diagnosis of epilepsy on scientific, clinical, and biographical grounds.
Retrospective debate; epilepsy is not used in the record.
disputed Hirschhorn N, Longsworth P. Was it epilepsy?: misdiagnosing Emily Dickinson (1830-1886). Perspect Biol Med. 2013;56(3):371-386. doi:10.1353/pbm.2013.0026 supports
D Her death came after two and a half years of ill health that followed a death in her family in October 1883 and a consequent nervous prostration; she later had two blackouts and was confined to bed for the seven months before her death.
Nervous prostration is a nineteenth-century term, not a modern diagnosis.
confirmed Emily Dickinson and Death supports
Emily Dickinson: The Later Years (1865-1886) supports
D Her letters mention severe headache and nausea, and her last illness ended in a coma with raspy, difficult breathing. confirmed Emily Dickinson and Death supports
D Her reclusiveness hampered her Amherst physician, because she would not admit him to her bedside to take a pulse. confirmed Emily Dickinson and Death supports
D She died in Amherst on May 15, 1886, aged 55; her physician entered Bright's disease as the cause on her death certificate, at the time a general diagnosis that included hypertensive symptoms as well as nephritis.
Bright's disease was a broad nineteenth-century label, not a specific modern kidney diagnosis.
confirmed Emily Dickinson and Death supports
Emily Dickinson: The Later Years (1865-1886) supports
R Researchers have concluded that she died of heart failure caused by severe hypertension; no documentary evidence records the yellow pallor and odor associated with nephritis.
A retrospective interpretation; no blood pressure or kidney test from her lifetime exists.
possible Emily Dickinson and Death supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate active confirmed both_with_link CLM-0013, CLM-0014
S Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension active confirmed both_with_link CLM-0014, CLM-0011
S Vitamin D deficiency with a mildly raised PTH in chronic kidney disease active confirmed active
S Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolved resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 1885-01-12 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1885-01-12 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1885-01-12 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 1885-01-12 Urea nitrogen [Mass/volume] in Serum or Plasma 21 mg/dL
Reference 6-21 mg/dL
http://loinc.org · 3094-0
S 1885-01-12 Creatinine [Mass/volume] in Serum or Plasma 1.2 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1885-01-12 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 54 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1885-01-12 Glucose [Mass/volume] in Serum or Plasma 92 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1885-01-12 Calcium [Mass/volume] in Serum or Plasma 9.3 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 1885-01-12 Phosphate [Mass/volume] in Serum or Plasma 3.8 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 1885-01-12 Parathyrin.intact [Mass/volume] in Serum or Plasma 74 pg/mL (high)
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 1885-01-12 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 21 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 1885-01-12 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 1885-01-12 Hemoglobin [Mass/volume] in Blood 12.3 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 1885-01-12 Cholesterol [Mass/volume] in Serum or Plasma 214 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 1885-01-12 Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 mg/dL
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 1885-01-12 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 134 mg/dL (high)
Reference <=99 mg/dL
http://loinc.org · 13457-7
S 1885-01-12 Triglyceride [Mass/volume] in Serum or Plasma 130 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 1885-01-12 Hemoglobin A1c/Hemoglobin.total in Blood 5.5%
Reference <=5.6%
http://loinc.org · 4548-4
S 1885-01-12 Thyrotropin [Units/volume] in Serum or Plasma 2.1 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 1885-01-12 Albumin/Creatinine [Mass Ratio] in Urine 240 mg/g (high)
Reference <=30 mg/g
http://loinc.org · 9318-7
S 1885-01-12 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 1 /[HPF]
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 1885-01-12 Kidney failure 2-year risk [Likelihood] by KFRE 0.5% http://loinc.org · 85624-5
S 1885-01-12 Kidney failure 5-year risk [Likelihood] by KFRE 1.6% http://loinc.org · 85625-2
S 1885-01-12 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 1885-01-12 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 http://loinc.org · 70274-6
S 1885-02-02 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1885-02-02 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1885-02-02 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 1885-02-02 Urea nitrogen [Mass/volume] in Serum or Plasma 22 mg/dL (high)
Reference 6-21 mg/dL
http://loinc.org · 3094-0
S 1885-02-02 Creatinine [Mass/volume] in Serum or Plasma 1.26 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1885-02-02 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 51 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1885-02-02 Glucose [Mass/volume] in Serum or Plasma 90 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1885-02-02 Albumin/Creatinine [Mass Ratio] in Urine 262 mg/g (high)
Reference <=30 mg/g
http://loinc.org · 9318-7
S 1885-03-02 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1885-03-02 Potassium [Moles/volume] in Serum or Plasma 4.8 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1885-03-02 Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 1885-03-02 Urea nitrogen [Mass/volume] in Serum or Plasma 23 mg/dL (high)
Reference 6-21 mg/dL
http://loinc.org · 3094-0
S 1885-03-02 Creatinine [Mass/volume] in Serum or Plasma 1.32 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1885-03-02 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 48 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1885-03-02 Glucose [Mass/volume] in Serum or Plasma 88 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1885-06-01 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1885-06-01 Potassium [Moles/volume] in Serum or Plasma 4.7 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1885-06-01 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 1885-06-01 Urea nitrogen [Mass/volume] in Serum or Plasma 22 mg/dL (high)
Reference 6-21 mg/dL
http://loinc.org · 3094-0
S 1885-06-01 Creatinine [Mass/volume] in Serum or Plasma 1.3 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1885-06-01 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 49 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1885-06-01 Glucose [Mass/volume] in Serum or Plasma 91 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1885-06-01 Albumin/Creatinine [Mass Ratio] in Urine 118 mg/g (high)
Reference <=30 mg/g
http://loinc.org · 9318-7
S 1885-06-01 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 1885-09-28 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1885-09-28 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1885-09-28 Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 1885-09-28 Urea nitrogen [Mass/volume] in Serum or Plasma 21 mg/dL
Reference 6-21 mg/dL
http://loinc.org · 3094-0
S 1885-09-28 Creatinine [Mass/volume] in Serum or Plasma 1.28 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1885-09-28 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 50 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1885-09-28 Glucose [Mass/volume] in Serum or Plasma 90 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1885-09-28 Albumin/Creatinine [Mass Ratio] in Urine 96 mg/g (high)
Reference <=30 mg/g
http://loinc.org · 9318-7
S 1885-09-28 Calcium [Mass/volume] in Serum or Plasma 9.4 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 1885-09-28 Phosphate [Mass/volume] in Serum or Plasma 3.6 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 1885-09-28 Parathyrin.intact [Mass/volume] in Serum or Plasma 61 pg/mL
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 1885-09-28 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 1885-04-20 Sodium [Moles/volume] in Serum or Plasma 136 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1885-04-20 Potassium [Moles/volume] in Serum or Plasma 5.3 mmol/L (high)
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1885-04-20 Carbon dioxide, total [Moles/volume] in Serum or Plasma 20 mmol/L (low)
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 1885-04-20 Urea nitrogen [Mass/volume] in Serum or Plasma 34 mg/dL (high)
Reference 6-21 mg/dL
http://loinc.org · 3094-0
S 1885-04-20 Creatinine [Mass/volume] in Serum or Plasma 1.66 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1885-04-20 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 36 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1885-04-20 Glucose [Mass/volume] in Serum or Plasma 86 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1885-10-19 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 1885-10-19 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 http://loinc.org · 70274-6
S 1885-10-19 Total score [AUDIT-C] 0 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
1885-01-12Body height163 cm8302-2S
1885-01-12Body weight54 kg29463-7S
1885-01-12Body mass index (BMI) [Ratio]20.3 kg/m239156-5S
1885-01-12Systolic blood pressure166 mm[Hg]8480-6S
1885-01-12Diastolic blood pressure98 mm[Hg]8462-4S
1885-01-12Heart rate78 /min8867-4S
1885-01-12Respiratory rate14 /min9279-1S
1885-01-12Body temperature36.6 Cel8310-5S
1885-01-12Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
1885-02-02Body height163 cm8302-2S
1885-02-02Body weight53.8 kg29463-7S
1885-02-02Body mass index (BMI) [Ratio]20.2 kg/m239156-5S
1885-02-02Systolic blood pressure148 mm[Hg]8480-6S
1885-02-02Diastolic blood pressure88 mm[Hg]8462-4S
1885-02-02Heart rate74 /min8867-4S
1885-02-02Respiratory rate14 /min9279-1S
1885-02-02Body temperature36.5 Cel8310-5S
1885-02-02Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
1885-03-02Body height163 cm8302-2S
1885-03-02Body weight53.6 kg29463-7S
1885-03-02Body mass index (BMI) [Ratio]20.2 kg/m239156-5S
1885-03-02Systolic blood pressure136 mm[Hg]8480-6S
1885-03-02Diastolic blood pressure84 mm[Hg]8462-4S
1885-03-02Heart rate72 /min8867-4S
1885-03-02Respiratory rate14 /min9279-1S
1885-03-02Body temperature36.6 Cel8310-5S
1885-03-02Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
1885-04-20Body height163 cm8302-2S
1885-04-20Body weight51.9 kg29463-7S
1885-04-20Body mass index (BMI) [Ratio]19.5 kg/m239156-5S
1885-04-20Systolic blood pressure104 mm[Hg]8480-6S
1885-04-20Diastolic blood pressure64 mm[Hg]8462-4S
1885-04-20Heart rate102 /min8867-4S
1885-04-20Respiratory rate18 /min9279-1S
1885-04-20Body temperature37.6 Cel8310-5S
1885-04-20Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1885-06-01Body height163 cm8302-2S
1885-06-01Body weight53.2 kg29463-7S
1885-06-01Body mass index (BMI) [Ratio]20 kg/m239156-5S
1885-06-01Systolic blood pressure124 mm[Hg]8480-6S
1885-06-01Diastolic blood pressure76 mm[Hg]8462-4S
1885-06-01Heart rate70 /min8867-4S
1885-06-01Respiratory rate14 /min9279-1S
1885-06-01Body temperature36.6 Cel8310-5S
1885-06-01Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
1885-09-28Body height163 cm8302-2S
1885-09-28Body weight53.4 kg29463-7S
1885-09-28Body mass index (BMI) [Ratio]20.1 kg/m239156-5S
1885-09-28Systolic blood pressure118 mm[Hg]8480-6S
1885-09-28Diastolic blood pressure74 mm[Hg]8462-4S
1885-09-28Heart rate68 /min8867-4S
1885-09-28Respiratory rate14 /min9279-1S
1885-09-28Body temperature36.5 Cel8310-5S
1885-09-28Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
1885-10-19Body height163 cm8302-2S
1885-10-19Body weight53.5 kg29463-7S
1885-10-19Body mass index (BMI) [Ratio]20.1 kg/m239156-5S
1885-10-19Systolic blood pressure120 mm[Hg]8480-6S
1885-10-19Diastolic blood pressure74 mm[Hg]8462-4S
1885-10-19Heart rate70 /min8867-4S
1885-10-19Respiratory rate14 /min9279-1S
1885-10-19Body temperature36.6 Cel8310-5S
1885-10-19Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness1885-09-28completed118/74 mmHg on losartan 100 mg and amlodipine 5 mg
Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor1885-06-01completed118 mg/g at three months and 96 mg/g at six months, from 240 mg/g
Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip1885-09-28activeeGFR 50 at the six-month review (54 at baseline); a temporary fall to 36 during gastroenteritis recovered
25-hydroxyvitamin D of at least 30 ng/mL1885-09-28completed36 ng/mL on vitamin D3; PTH 61 pg/mL
Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic1885-09-28completedTwo clinic trips in the episode, each combining several tasks; all other visits at home or by video

Interventions

InterventionStatusGuideline
Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percentcompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021
If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks latercompletedGL-CMID-2026, GL-KDIGO-CKD-2024
Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFRcompletedGL-CMID-2026, GL-KDIGO-CKD-2024
Nephrology consultation to confirm the cause of chronic kidney disease with albuminuria in a woman in her fifties and to advise on treatment and follow-upcompletedGL-CMID-2026, GL-KDIGO-CKD-2024
Sick-day guidance: during vomiting, diarrhea, or poor fluid intake, pause losartan, dapagliflozin, and any other blood pressure medicine, drink fluids, call the clinic, and restart after 24 to 48 hours of normal eating and drinkingcompletedGL-CMID-2026, GL-KDIGO-CKD-2024
CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearlycompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017
Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTHcompletedGL-CMID-2026, GL-KDIGO-CKD-2024
Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccinescompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-CDC-IMZ-2026
Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointmentcompletedGL-CMID-2026, GL-KDIGO-CKD-2024
PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairmentcompletedGL-CMID-2026, GL-USPSTF-ANX-2023, GL-USPSTF-DEP-2023
Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walkingcompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Emily Dickinson: Her Childhood and Youth (1830-1855) Emily Dickinson Museum other
SRC-0002 Emily Dickinson's Health Emily Dickinson Museum other
SRC-0003 Emily Dickinson: The Later Years (1865-1886) Emily Dickinson Museum other
SRC-0004 Emily Dickinson and Death Emily Dickinson Museum other
SRC-0005 Blanchard DL. Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD. Arch Ophthalmol. 2012;130(12):1591-1595. doi:10.1001/archophthalmol.2012.2365 PubMed (PMID 23229703) scholarly
SRC-0006 Hirschhorn N, Longsworth P. Was it epilepsy?: misdiagnosing Emily Dickinson (1830-1886). Perspect Biol Med. 2013;56(3):371-386. doi:10.1353/pbm.2013.0026 PubMed (PMID 24375119) scholarly
SRC-0007 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check ARB titration and SGLT2 inhibitor use without diabetes, the sick-day plan, home and video vital signs, and the recorded deviation.
provenance reviewnot_startedFour Emily Dickinson Museum pages and two PubMed abstracts logged. Bright's disease on the death certificate is D; hypertensive heart failure, iritis, anxiety, and epilepsy are R. Family history is left empty so that no health facts are attributed to her relatives.
safe messaging reviewnot_startedMood and anxiety screens are below the thresholds for a safety assessment; her withdrawal is not labeled a disorder; her death is recorded without graphic detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.